Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia
Prince Alfred Singh, Medical Officer at Addu Equatorial Hospital (AEH), shared a post on LinkedIn:
“Understanding Antithrombin III Deficiency: A High-Risk Thrombophilia
Antithrombin III (AT III) plays a critical role as the body’s natural anticoagulant – primarily inhibiting thrombin (IIa) and factor Xa to prevent excessive clot formation.
What happens in AT III deficiency?
A reduction in this key inhibitor shifts the hemostatic balance toward thrombosis, making it one of the most clinically significant inherited thrombophilias.
Key Facts:
- Inherited in an autosomal dominant pattern
- Prevalence: approximately 1 in 3,000 individuals
- Strongly associated with recurrent venous thromboembolism (VTE)
- Arterial events are less common but can occur
Risk Perspective:
Compared to other thrombophilias such as Factor V Leiden or Protein C deficiency, AT III deficiency carries one of the highest relative risks for VTE.
Clinical Management Insights:
- Many patients require long-term anticoagulation (e.g., warfarin)
- Heparin resistance can occur due to low AT levels
- In pregnancy: heparin-based therapy is preferred
- Consider AT concentrate in selected high-risk scenarios
Clinical Takeaway:
- Early recognition is essential—especially in patients with:
- Recurrent unexplained VTE
- Strong family history of thrombosis
- Thrombosis at a young age
A tailored, lifelong management strategy can significantly reduce morbidity and prevent life-threatening complications.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 14:16Erin VanDyke: Next Generation Is Leading the Way in Pediatric VTE Care
-
Apr 15, 2026, 14:13Shahzeb Hassan: Pulmonary Embolism – What to Do When Every Minute Matters
-
Apr 15, 2026, 14:06Hossam El Benawi: Intensive Blood Pressure Reduction May Worsen Outcomes After Thrombectomy
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy